{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:40:31Z","timestamp":1768873231351,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s11916-007-0231-3","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T16:09:18Z","timestamp":1196957358000},"page":"440-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Update on gout: Pathophysiology and potential treatments"],"prefix":"10.1007","volume":"11","author":[{"given":"Aryeh M.","family":"Abeles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Y.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce N.","family":"Cronstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,5]]},"reference":[{"issue":"Suppl1","key":"231_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar1906","volume":"8","author":"G. Nuki","year":"2006","unstructured":"Nuki G, Simkin PA: A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006, 8(Suppl 1):S1.","journal-title":"Arthritis Res Ther"},{"key":"231_CR2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0889-857X(21)00969-8","volume":"14","author":"R.A. Terkeltaub","year":"1988","unstructured":"Terkeltaub RA, Ginsberg MH: The inflammatory reaction to crystals. Rheum Dis Clin North Am 1988, 14:353\u2013364.","journal-title":"Rheum Dis Clin North Am"},{"key":"231_CR3","first-page":"82","volume":"64","author":"R. Terkeltaub","year":"2006","unstructured":"Terkeltaub R: Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis 2006, 64:82\u201386.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"231_CR4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-857X(21)00964-9","volume":"14","author":"H.R. Schumacher Jr","year":"1988","unstructured":"Schumacher HR Jr: Pathology of crystal deposition diseases. Rheum Dis Clin North Am 1988, 14:269\u2013288.","journal-title":"Rheum Dis Clin North Am"},{"key":"231_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00002281-199705000-00012","volume":"9","author":"H.R. Schumacher Jr","year":"1997","unstructured":"Schumacher HR Jr: Crystal deposition disease. Curr Opin Rheumatol 1997, 9:251\u2013252.","journal-title":"Curr Opin Rheumatol"},{"key":"231_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cell.2006.08.002","volume":"126","author":"Y. Ogura","year":"2006","unstructured":"Ogura Y, Sutterwala FS, Flavell RA: The inflammasome: first line of the immune response to cell stress. Cell 2006, 126:659\u2013662.","journal-title":"Cell"},{"key":"231_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F. Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417\u2013426.","journal-title":"Mol Cell"},{"key":"231_CR8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa061592","volume":"356","author":"Y. Jin","year":"2007","unstructured":"Jin Y, Mailloux CM, Gowan K, et al.: NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007, 356:1216\u20131225.","journal-title":"N Engl J Med"},{"key":"231_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F. Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237\u2013241.","journal-title":"Nature"},{"key":"231_CR10","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/art.21238","volume":"52","author":"R. Liu-Bryan","year":"2005","unstructured":"Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936\u20132946.","journal-title":"Arthritis Rheum"},{"key":"231_CR11","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1172\/JCI28075","volume":"116","author":"C.J. Chen","year":"2006","unstructured":"Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262\u20132271.","journal-title":"J Clin Invest"},{"key":"231_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T","volume":"43","author":"R. Liu","year":"2000","unstructured":"Liu R, O\u2019Connell M, Johnson K, et al.: Extracellular signal-regulated kinase 1\/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000, 43:1145\u20131155.","journal-title":"Arthritis Rheum"},{"key":"231_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nature01991","volume":"425","author":"Y. Shi","year":"2003","unstructured":"Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516\u2013521.","journal-title":"Nature"},{"key":"231_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","volume":"20","author":"C.A. Janeway Jr","year":"2002","unstructured":"Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197\u2013216.","journal-title":"Annu Rev Immunol"},{"key":"231_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","volume":"13","author":"S. Gallucci","year":"2001","unstructured":"Gallucci S, Matzinger P: Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13:114\u2013119.","journal-title":"Curr Opin Immunol"},{"key":"231_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.molmed.2004.04.001","volume":"10","author":"M. Skoberne","year":"2004","unstructured":"Skoberne M, Beignon AS, Bhardwaj N: Danger signals: a time and space continuum. Trends Mol Med 2004, 10:251\u2013257.","journal-title":"Trends Mol Med"},{"key":"231_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/sj.embor.7400505","volume":"6","author":"N.W. Andrews","year":"2005","unstructured":"Andrews NW: Membrane repair and immunological danger. EMBO Rep 2005, 6:826\u2013830.","journal-title":"EMBO Rep"},{"key":"231_CR18","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1158\/0008-5472.CAN-04-1586","volume":"64","author":"D.E. Hu","year":"2004","unstructured":"Hu DE, Moore AM, Thomsen LL, Brindle KM: Uric acid promotes tumor immune rejection. Cancer Res 2004, 64:5059\u20135062.","journal-title":"Cancer Res"},{"key":"231_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF00163854","volume":"34","author":"X.W. Wu","year":"1992","unstructured":"Wu XW, Muzny DM, Lee CC, Caskey CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992, 34:78\u201384.","journal-title":"J Mol Evol"},{"key":"231_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000028589.66335.AA","volume":"40","author":"S. Watanabe","year":"2002","unstructured":"Watanabe S, Kang DH, Feng L, et al.: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002, 40:355\u2013360.","journal-title":"Hypertension"},{"key":"231_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M. Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, et al.: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101\u20131106.","journal-title":"Hypertension"},{"key":"231_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1523-1755.2004.00729.x","volume":"66","author":"D.I. Feig","year":"2004","unstructured":"Feig DI, Nakagawa T, Karumanchi SA, et al.: Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004, 66:281\u2013287.","journal-title":"Kidney Int"},{"key":"231_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/01.HYP.0000223447.53155.d5","volume":"48","author":"D.I. Feig","year":"2006","unstructured":"Feig DI, Rodriguez-Iturbe B, Nakagawa T, Johnson RJ: Nephron number, uric acid, and renal microvascular disease in the pathogenesis of essential hypertension. Hypertension 2006, 48:25\u201326.","journal-title":"Hypertension"},{"key":"231_CR24","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1161\/01.HYP.0000072820.07472.3B","volume":"41","author":"J. Kanellis","year":"2003","unstructured":"Kanellis J, Watanabe S, Li JH, et al.: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287\u20131293.","journal-title":"Hypertension"},{"key":"231_CR25","doi-asserted-by":"crossref","first-page":"F1105","DOI":"10.1152\/ajprenal.00170.2002","volume":"283","author":"L.G. Sanchez-Lozada","year":"2002","unstructured":"Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al.: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002, 283:F1105\u2013F1110.","journal-title":"Am J Physiol Renal Physiol"},{"key":"231_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1053\/j.jrn.2006.10.013","volume":"17","author":"D.I. Feig","year":"2007","unstructured":"Feig DI, Johnson RJ: The role of uric acid in pediatric hypertension. J Ren Nutr 2007, 17:79\u201383.","journal-title":"J Ren Nutr"},{"key":"231_CR27","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/00004872-199917070-00001","volume":"17","author":"J.G. Puig","year":"1999","unstructured":"Puig JG, Ruilope LM: Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999, 17:869\u2013872.","journal-title":"J Hypertens"},{"key":"231_CR28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/oxfordjournals.aje.a117634","volume":"142","author":"J. Lee","year":"1995","unstructured":"Lee J, Sparrow D, Vokonas PS, et al.: Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995, 142:288\u2013294.","journal-title":"Am J Epidemiol"},{"key":"231_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","volume":"131","author":"B.F. Culleton","year":"1999","unstructured":"Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7\u201313.","journal-title":"Ann Intern Med"},{"key":"231_CR30","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","volume":"283","author":"J. Fang","year":"2000","unstructured":"Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971\u20131992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404\u20132410.","journal-title":"JAMA"},{"key":"231_CR31","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","volume":"164","author":"L.K. Niskanen","year":"2004","unstructured":"Niskanen LK, Laaksonen DE, Nyyssonen K, et al.: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004, 164:1546\u20131551.","journal-title":"Arch Intern Med"},{"key":"231_CR32","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E. Krishnan","year":"2006","unstructured":"Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54:2688\u20132696.","journal-title":"Arthritis Rheum"},{"key":"231_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1185\/030079904125002982","volume":"20","author":"M. Alderman","year":"2004","unstructured":"Alderman M, Aiyer KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004, 20:369\u2013379.","journal-title":"Curr Med Res Opin"},{"key":"231_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.0954-6820.1988.tb19625.x","volume":"224","author":"C. Bengtsson","year":"1988","unstructured":"Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J: Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988, 224:549\u2013555.","journal-title":"Acta Med Scand"},{"key":"231_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0895-4356(89)90061-9","volume":"42","author":"W. Levine","year":"1989","unstructured":"Levine W, Dyer AR, Shekelle RB, et al.: Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989, 42:257\u2013267.","journal-title":"J Clin Epidemiol"},{"key":"231_CR36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/01.HYP.37.4.1069","volume":"37","author":"J.G. Wang","year":"2001","unstructured":"Wang JG, Staessen JA, Fagard RH, et al.: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001, 37:1069\u20131074.","journal-title":"Hypertension"},{"key":"231_CR37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/oxfordjournals.aje.a117479","volume":"141","author":"D.S. Freedman","year":"1995","unstructured":"Freedman DS, Williamson DF, Gunter EW, Byers T: Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995, 141:637\u2013644.","journal-title":"Am J Epidemiol"},{"key":"231_CR38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/00004872-200018080-00021","volume":"18","author":"L.V. Franse","year":"2000","unstructured":"Franse LV, Pahor M, Di Bari M, et al.: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000, 18:1149\u20131154.","journal-title":"J Hypertens"},{"key":"231_CR39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.0954-6820.1982.tb08521.x","volume":"668","author":"A. Reunanen","year":"1982","unstructured":"Reunanen A, Takkunen H, Knekt P, Aromaa A: Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl 1982, 668:49\u201359.","journal-title":"Acta Med Scand Suppl"},{"key":"231_CR40","first-page":"2403","volume":"29","author":"E. Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, et al.: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403\u20132406.","journal-title":"J Rheumatol"},{"key":"231_CR41","first-page":"1582","volume":"31","author":"K.L. Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004, 31:1582\u20131587.","journal-title":"J Rheumatol"},{"key":"231_CR42","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"H.K. Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, et al.: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350:1093\u20131103.","journal-title":"N Engl J Med"},{"key":"231_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/art.20761","volume":"52","author":"H.K. Choi","year":"2005","unstructured":"Choi HK, Liu S, Curhan G: Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005, 52:283\u2013289.","journal-title":"Arthritis Rheum"},{"key":"231_CR44","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","volume":"363","author":"H.K. Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, et al.: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004, 363:1277\u20131281.","journal-title":"Lancet"},{"issue":"Suppl1","key":"231_CR45","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/ar1909","volume":"8","author":"R. Terkeltaub","year":"2006","unstructured":"Terkeltaub R, Bushinsky DA, Becker MA: Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006, 8(Suppl 1):S4.","journal-title":"Arthritis Res Ther"},{"key":"231_CR46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A. Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, et al.: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002, 417:447\u2013452.","journal-title":"Nature"},{"key":"231_CR47","first-page":"187","volume":"276","author":"M. Hatch","year":"1996","unstructured":"Hatch M, Freel RW, Shahinfar S, Vaziri ND: Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. J Pharmacol Exp Ther 1996, 276:187\u2013193.","journal-title":"J Pharmacol Exp Ther"},{"key":"231_CR48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1172\/JCI12471","volume":"107","author":"M.S. Lipkowitz","year":"2001","unstructured":"Lipkowitz MS, Leal-Pinto E, Rappoport JZ, et al.: Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 2001, 107:1103\u20131115.","journal-title":"J Clin Invest"},{"key":"231_CR49","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1126\/science.156.3774.521","volume":"156","author":"S.E. Malawista","year":"1967","unstructured":"Malawista SE, Bensch KG: Human polymorphonuclear leukocytes: demonstration of microtubules and effect of colchicine. Science 1967, 156:521\u2013522.","journal-title":"Science"},{"key":"231_CR50","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","volume":"96","author":"B.N. Cronstein","year":"1995","unstructured":"Cronstein BN, Molad Y, Reibman J, et al.: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994\u20131002.","journal-title":"J Clin Invest"},{"key":"231_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00002281-199206000-00002","volume":"4","author":"S.B. Abramson","year":"1992","unstructured":"Abramson SB: Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1992, 4:295\u2013300.","journal-title":"Curr Opin Rheumatol"},{"key":"231_CR52","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMcp030733","volume":"349","author":"R.A. Terkeltaub","year":"2003","unstructured":"Terkeltaub RA: Clinical practice. Gout. N Engl J Med 2003, 349:1647\u20131655.","journal-title":"N Engl J Med"},{"key":"231_CR53","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"M.A. Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450\u20132461.","journal-title":"N Engl J Med"},{"key":"231_CR54","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1517\/13543784.14.7.893","volume":"14","author":"H.R. Schumacher Jr","year":"2005","unstructured":"Schumacher HR Jr: Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 2005, 14:893\u2013903.","journal-title":"Expert Opin Investig Drugs"},{"key":"231_CR55","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ncponc0581","volume":"3","author":"E. Rampello","year":"2006","unstructured":"Rampello E, Fricia T, Malaguarnera M: The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006, 3:438\u2013447.","journal-title":"Nat Clin Pract Oncol"},{"key":"231_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ncprheum0214","volume":"2","author":"P. Richette","year":"2006","unstructured":"Richette P, Bardin T: Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2006, 2:338\u2013342; quiz 343.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"231_CR57","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/art.22403","volume":"56","author":"J.S. Sundy","year":"2007","unstructured":"Sundy JS, Ganson NJ, Kelly SJ, et al.: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021\u20131028.","journal-title":"Arthritis Rheum"},{"key":"231_CR58","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A. So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.","journal-title":"Arthritis Res Ther"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-007-0231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-007-0231-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-007-0231-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-007-0231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T03:12:11Z","timestamp":1708398731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-007-0231-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["231"],"URL":"https:\/\/doi.org\/10.1007\/s11916-007-0231-3","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"5 December 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}